CRISPR-based smart nanodevice using DNA end patterns for precise cancer treatment

LogiCas achieves ~91% tumor inhibition in a nude mouse model with targeted drug release.

• A protein and nucleic acid dual-biomarker-responsive system is developed for precise tumor therapy.
• The system operates through a dual-lock mechanism that requires specific protein and RNA inputs for activation.
• Activation of the Cas12a enzyme leads to the cleavage of a therapeutic agent, initiating photodynamic therapy.
• Photodynamic therapy generates reactive oxygen species, which promote the translocation of a key protein to enhance therapeutic effects.
• The approach demonstrates minimal systemic toxicity while effectively targeting tumor sites.

Simplified